Regulatory T cells and proliferating lymphocytes (Tregs and proliferating lymphocytes)

Regulatory T cells (Tregs) and proliferating lymphocytes represent critical cellular targets in the fields of oncology and immunology. Tregs are a specialized subset of T cells, typically defined by the expression of CD4, CD25, and the master transcription factor Foxp3, which function to maintain immune homeostasis and prevent autoimmunity by suppressing excessive immune responses. In cancer, Tregs often infiltrate the tumor microenvironment and facilitate immune evasion by inhibiting the activity of effector T cells and natural killer cells. Proliferating lymphocytes include activated T and B cells undergoing rapid clonal expansion during an immune challenge or within lymphoproliferative disorders. Therapeutic strategies targeting these populations often involve the use of low-dose cytotoxic agents like cyclophosphamide to selectively deplete suppressive Tregs or the use of IL-2-based therapies to modulate their activity. Molecular markers such as the IL-2 receptor alpha chain (CD25) serve as primary points of pharmacological intervention for drugs like denileukin diftitox and daclizumab.

Other names

Regulatory T-lymphocytesTregsCD4+ CD25+ Foxp3+ T cellsActivated lymphocytesProliferating T cellsSuppressor T cells

Selective depletion of regulatory T cells, inhibition of DNA synthesis in proliferating cells via alkylation, and modulation of the Interleukin-2 receptor signaling pathway.